We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Diagnostic Value of PI-RADS v2.1 in Patients with a History of Transurethral Resection of the Prostate (TURP).
- Authors
Liu, Jiazhou; Pan, Shihang; Dong, Liang; Wu, Guangyu; Wang, Jiayi; Wang, Yan; Qian, Hongyang; Dong, Baijun; Pan, Jiahua; Zhu, Yinjie; Xue, Wei
- Abstract
To explore the diagnostic value of the Prostate Imaging–Reporting and Data System version 2.1 (PI-RADS v2.1) for clinically significant prostate cancer (CSPCa) in patients with a history of transurethral resection of the prostate (TURP), we conducted a retrospective study of 102 patients who underwent systematic prostate biopsies with TURP history. ROC analyses and logistic regression analyses were performed to demonstrate the diagnostic value of PI-RADS v2.1 and other clinical characteristics, including PSA and free/total PSA (F/T PSA). Of 102 patients, 43 were diagnosed with CSPCa. In ROC analysis, PSA, F/T PSA, and PI-RADS v2.1 demonstrated significant diagnostic value in detecting CSPCa in our cohort (AUC 0.710 (95%CI 0.608–0.812), AUC 0.768 (95%CI 0.676–0.860), AUC 0.777 (95%CI 0.688–0.867), respectively). Further, PI-RADS v2.1 scores of the peripheral and transitional zones were analyzed separately. In ROC analysis, PI-RADS v2.1 remained valuable in identifying peripheral-zone CSPCa (AUC 0.780 (95%CI 0.665–0.854; p < 0.001)) while having limited capability in distinguishing transitional zone lesions (AUC 0.533 (95%CI 0.410–0.557; p = 0.594)). PSA and F/T PSA retain significant diagnostic value for CSPCa in patients with TURP history. PI-RADS v2.1 is reliable for detecting peripheral-zone CSPCa but has limited diagnostic value when assessing transitional zone lesions.
- Subjects
TRANSURETHRAL prostatectomy; PROSTATE cancer treatment; PROSTATE surgery; PROSTATE-specific antigen; MAGNETIC resonance imaging
- Publication
Current Oncology, 2022, Vol 29, Issue 9, p6373
- ISSN
1198-0052
- Publication type
Article
- DOI
10.3390/curroncol29090502